Company intelligence / Profile preview

Blue Harbour

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Multiple antibodies (e.g., anti-CTLA-4, anti-TSLP) in clinical development; partnered and out-licensed programs advancing globally; first-in-class/next-gen antibody technologies

Therapeutic areas: OncologyPulmonologyImmunology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugateRecombinant proteinBiologic
Industry: Biotech

Partnerships

AbbVie (license agreement)Windward Bio (out-licensing of HBM9378/SKB378)Sichuan Kelun Biotech (development partner for HBM9378/SKB378)

Beyond the preview

Go deeper on Blue Harbour.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blue Harbour.

Explore the full profile